{
    "nctId": "NCT02051751",
    "briefTitle": "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer",
    "officialTitle": "A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast Neoplasms, Head and Neck Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 19,
    "primaryOutcomeMeasure": "Dose escalation : Dose Limiting Toxicity (DLT)",
    "eligibilityCriteria": "Inclusion criteria For entire trial:\n\n1. - Adult \\> or = 18 years old\n2. - has signed the Informed Consent Form (ICF)\n3. - has at least one measurable or non-measurable disease as per RECIST 1.1\n4. - has tumor tissue available for the analysis as described in the protocol\n5. - has adequate bone marrow and organ function as defined in the protocol\n6. - is able to swallow and retain oral medication for the dose escalation part, ALL above PLUS\n7. - has a histologically-confirmed, advanced unresectable solid tumors who have progressed on standard therapy (or not been able to tolerate) within three months before screening/baseline visit or for whom no standard anticancer therapy exists.\n8. - has an Eastern Cooperative Oncology Group (ECOG) performance status \u22642 For dose expansion part, patient has ALL of above first six criteria PLUS either: 9- has a histologically/cytologically-confirmed HNSCC as detailed in the protocol and an ECOG performance status \u2264 1 or:\n\n   * Patient is a Female with a histologically and/or cytologically confirmed diagnosis of breast cancer as detailed in the protocol and an ECOG performance status \u2264 1\n\nCommon exclusion criteria to Dose escalation and Dose expansion parts:\n\n1. - has received previous treatment with a PI3K or AKT inhibitor as described in the protocol\n2. - has a known hypersensitivity to paclitaxel or other products containing Cremophor\n3. - has a contraindication to use the standard pre-treatment for paclitaxel\n4. - has a primary central nervous system (CNS) tumor or CNS tumor involvement as detailed in the protocol\n5. - has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy\n6. - has received radiotherapy \\> or = 4 weeks prior to starting study drugs, with exception of palliative radiotherapy, who has not recovered from side effects of such therapy to baseline or Grade \u2264 1 and/or from whom \u2265 30% of the bone marrow was irradiated\n7. - has peripheral sensory neuropathy with functional impairment (CTC grade 2 neuropathy or higher)\n8. - has undergone major surgery \u2264 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure\n9. - has a clinically significant cardiac disease or impaired cardiac function as detailed in the protocol\n10. - is currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment\n11. - has diabetes mellitus requiring insulin treatment and/or with clinical signs\n12. - has impaired gastrointestinal (GI) function or GI disease as described in the protocol\n13. - has a known positive serology for human immunodeficiency virus (HIV), active Hepatitis B, and/or active Hepatitis C infection\n14. - has any other condition that would, in the Investigator's judgment, preclude patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures\n15. - is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzymes CYP3A or CYP2C8 as detailed in the protocol\n16. - is currently receiving treatment with agents that are metabolized solely by CYP3A and/or have a narrow therapeutic window\n17. - has a history of another malignancy within 2 years prior to starting study treatment, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix\n18. - Patient has a history of non-compliance to medical regimen or inability to grant consent\n19. - Pregnant or nursing (lactating) women\n20. - does not apply highly effective contraception during the study and through the duration as defined in the protocol\n\nFor the HNSCC patient's cohort additional exclusion criteria are:\n\n21- Treatment with more than one prior chemotherapy for recurrent/metastatic disease as detailed in the protocol 22- Prior taxane treatment for metastatic disease additional exclusion criteria for breast cancer patients' cohort:\n\n- has received any prior cytotoxic therapy for the inoperable locally advanced (recurrent or progressive) or metastatic disease, or who had a progression/recurrent disease within 6 months after completion of an adjuvant/neoadjuvant therapy as described in the protocol\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}